Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) received a $24.00 target price from investment analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, May 9th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 306.78% from the stock’s previous close.
A number of other brokerages also recently commented on CRBP. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Saturday, May 6th. JMP Securities restated an “outperform” rating and set a $27.00 target price (up previously from $20.00) on shares of Corbus Pharmaceuticals Holdings in a research note on Monday, April 3rd.
Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 5.90 on Tuesday. The firm’s market cap is $296.29 million. The stock’s 50 day moving average price is $6.46 and its 200 day moving average price is $7.60. Corbus Pharmaceuticals Holdings has a 12-month low of $2.62 and a 12-month high of $10.78.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The business had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 874.41% and a negative return on equity of 117.78%. On average, equities research analysts predict that Corbus Pharmaceuticals Holdings will post ($0.77) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Corbus Pharmaceuticals Holdings, Inc. (CRBP) Given a $24.00 Price Target at Cantor Fitzgerald” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/06/15/corbus-pharmaceuticals-holdings-inc-crbp-given-a-24-00-price-target-at-cantor-fitzgerald-updated-updated-updated.html.
In other news, insider Barbara White bought 4,233 shares of the company’s stock in a transaction dated Friday, March 17th. The stock was bought at an average cost of $9.49 per share, for a total transaction of $40,171.17. Following the transaction, the insider now owns 166,300 shares of the company’s stock, valued at $1,578,187. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought a total of 16,618 shares of company stock valued at $115,880 over the last 90 days. Corporate insiders own 11.60% of the company’s stock.
A number of large investors have recently bought and sold shares of the company. Knoll Capital Management LP acquired a new stake in Corbus Pharmaceuticals Holdings during the third quarter worth $16,717,000. FMR LLC purchased a new position in shares of Corbus Pharmaceuticals Holdings during the fourth quarter worth about $9,331,000. Fosun International Ltd purchased a new position in shares of Corbus Pharmaceuticals Holdings during the third quarter worth about $4,753,000. KCG Holdings Inc. increased its position in shares of Corbus Pharmaceuticals Holdings by 1,066.5% in the first quarter. KCG Holdings Inc. now owns 141,209 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 129,104 shares during the period. Finally, Laurion Capital Management LP purchased a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter worth about $1,015,000. 28.26% of the stock is currently owned by hedge funds and other institutional investors.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
What are top analysts saying about Corbus Pharmaceuticals Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corbus Pharmaceuticals Holdings Inc. and related companies.